Last checked at 22 Mar 2022 07:00
Kanabo Group Plc
("Kanabo" or the "Company")
Board Changes
Kanabo Group Plc (LSE:KNB), the pan-European medical cannabis Company focussing on the development and distribution of cannabis-derived products for medical patients and wellness CBD consumers, announces the appointment of Gil Efron to the Company's Board as a non-executive director, with effect from March 21st, 2022.
Kanabo's Audit Committee is currently chaired by Uzi Danino, who will retire as a Non-Executive Director to focus on his other business interests. Gil will take over as chair of the Audit Committee following Uzi's retirement.
Gil is serving as President and Chief Financial Officer of NASDAQ and TASE dual-listed Purple Biotech Ltd., a clinical-stage company (PPBT) since June 2021, having previously held the position of Deputy Chief Executive Officer and Chief Financial Officer from October 2018. Prior to his current tenure at Purple Biotech, Gil served as Deputy CEO and CFO of Kamada Ltd., a NASDAQ and TASE dual-listed plasma-derived protein therapeutics company between 2011-2017.
Commenting on the appointment Avihu Tamir, founder and CEO of Kanabo, said: "We are delighted to welcome Gil to the board. His wealth of experience in the capital market will be an excellent addition to Kanabo's Board, as well as his vast business and financial management experience. The Board and I would like to thank Uzi for his tireless dedication in bringing Kanabo to the listed market in the UK. We have benefited greatly from his experience and counsel over the past 3.5 years and wish him well in all his future endeavours."
There are no details to be disclosed under paragraphs 9.6.13 (2) to (6) of the Listing Rules.
The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.]
For further information, please visit http://www.kanabogroup.com/ or contact the following:
Kanabo Group Plc | Via Vox Markets |
Avihu Tamir, CEO |
|
Peterhouse Capital Ltd (Financial Adviser) | Tel: +44 (0)20 7469 0930 |
Eran Zucker / Lauren Riley |
|
Peterhouse Capital Ltd (Corporate Broker) | Tel: +44 (0)20 7469 0930 |
Lucy Williams / Charles Goodfellow | |
Vox Markets (Investor Relations) | KanaboGroup@voxmarkets.co.uk |
Kat Perez | kperez@voxmarkets.co.uk |
About Kanabo Group Plc
Kanabo Group Plc is creating a new standard in the medical cannabis industry to improve the well-being of millions of people around the world by providing a better alternative to the smoking of medicinal cannabis flowers. Kanabo, which was the first medicinal cannabis company to IPO on London Stock Exchange, has a focus on the distribution of cannabis-derived products for medical patients and non-THC products for CBD consumers. It has conducted extensive Research & Development to produce high-quality cannabis extract formulas, innovative medical-grade vaporizers, and various non-smoking consumption solutions. Kanabo sells a range of medical cannabis products and wellness CBD products in the Primary Markets, including its VapePod, which delivers a metered dose with every inhalation.